Blogs

Market to Reach $3.84 Billion by 2029, Driven by Rising Cancer Burden, Diagnostic Accuracy Demand, and Personalized Medicine

Market to Reach .84 Billion by 2029, Driven by Rising Cancer Burden, Diagnostic Accuracy Demand, and Personalized Medicine

Company Logo
Company Logo

AI pathology quality control market opportunities include rising demand due to cancer prevalence, the advantages of AI in diagnostic accuracy, automated quality assurance needs, precision medicine expansion, and cloud-based pathology adoption. Growth is driven by a shortage of pathologists and investment in AI startups.

Artificial Intelligence (AI) Pathology Quality Control Market

Artificial Intelligence (AI) Pathology Quality Control Market
Artificial Intelligence (AI) Pathology Quality Control Market

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) — The “Artificial Intelligence (AI) Pathology Quality Control Market Report 2025” has been added to ResearchAndMarkets.com’s offering.

The artificial intelligence (AI) pathology quality control market is experiencing remarkable growth, projected to expand from $1.46 billion in 2024 to $3.84 billion by 2029, at a compound annual growth rate (CAGR) of 21.2%. This surge is driven by factors such as rising cancer and chronic disease prevalence, increased demand for diagnostic accuracy, a shortage of skilled pathologists, higher healthcare expenditures, and the expansion of personalized medicine.

Personalized medicine is increasingly significant due to advancements in genomics, facilitating precise genetic variation identification and targeted treatments. AI-powered pathology quality control is integral in this domain, delivering reliable diagnostic insights essential for individualized treatment plans. The Personalized Medicine Coalition noted a rise in FDA-approved personalized medicines, with 26 new approvals in 2023, up from 12 in 2022, boosting the AI pathology quality control market.

Key players in the market are developing advanced AI solutions to enhance diagnostic precision and streamline laboratory workflows. Notably, PathAI launched Artifact Detect 1 in November 2023, enhancing its AISight platform by automating artifact detection and quantification in pathology slides. This innovation improves diagnostic accuracy and efficiency by preventing misdiagnoses and unnecessary rescans. Moreover, Molbio Diagnostics’ acquisition of a majority stake in OptraSCAN Inc. in November 2024, with a $30 million investment, allows the company to expand its digital and AI-driven pathology presence, enhancing its global reach and diagnostic portfolio.

The market consists of major players such as Roche Diagnostics GmbH, Danaher Corporation, Philips Healthcare, Agilent Technologies Inc., Hologic Inc., Clinisys Group Ltd., Sectra AB, PathAI Inc., OptraSCAN Inc., Paige.AI Inc., Proscia Inc., Quibim S.L., 3DHISTECH Ltd., Visiopharm A/S, Indica Labs Inc., Ibex Medical Analytics Ltd., Aiosyn B.V., DeepBio Inc., Nucleai Ltd., and Gestalt Diagnostics LLC.

Leave a Reply

Your email address will not be published. Required fields are marked *